We are monitoring the impact of COVID-19 on North America Biomarkers Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 165
Share on
Share on

North America Biomarkers Market Research Report – Segmented by Product, By Type, By Disease Indications & By Country (U.S, Canada and Rest of North America) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 165
Pages: 135

North America Biomarkers Market Size (2021 to 2026)

The North American biomarkers market is expected to reach USD 47.65 billion by 2026 from USD 27.28 billion in 2021, growing at a CAGR of 11.80% during the forecast period.

The biomarkers market in North America is primarily driven by the growing relevance of companies’ diagnostics, the rising global prevalence of cancer, increased funds and grants for biomarker research, and continual product improvements. Growing need for biomarkers in the diagnostic area, rising research and development expenditures, and rising healthcare expenditure are further accelerating the growth rate of the North American biomarkers market. In addition, the rising prevalence of sickness to boost the productivity of pharmaceuticals in pharmaceutical businesses and people’s demand for disease prevention by detecting as early as feasible is fueling market expansion.

Validating biomarkers takes a long time due to inconsistencies in their efficacy in sickness diagnosis. As a result, the validation process becomes time-consuming (about 15 years when combined with the time required for FDA clearance) and costly. With a few exceptions, the process and timing for generating and validating biomarkers are similar because different biomarkers have similar development and validation process steps. Surrogate endpoints are the most expensive to develop and validate, especially in clinical studies, due to the significant clinical validation required.

Impact of COVID-19 on the North American biomarkers market:

The COVID-19 outbreak caused widespread disruption in nearly every industry. In its realm, the healthcare sector also saw an unparalleled influence. This is not the situation in the biomarker market, where biomarkers are crucial in developing chronic care drugs and where the government and pharmaceutical companies will invest heavily, stifling market growth. To assist COVID-19 research, the market’s main manufacturers produced a variety of assays and assay kits.

The COVID-19 study has helped researchers untangled the complicated picture of coronavirus by developing breakthrough biomarker technologies and a wide range of goods such as antibody tests and PCR testing. As a result, the COVID-19 has had a beneficial impact on the North American biomarkers market.

This research report on the North American Biomarkers Market has been segmented and sub-segmented into the following categories:

By Product: 

  • Consumables
  • Software
  • Services

By Type: 

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Validation Biomarkers

By Application: 

  • Diagnostics Developments
  • Drug Discovery & Developments
  • Personalized Medicine
  • Disease Risk Assessment

By Disease Indications: 

  • Cancer
  • Cardiovascular
  • Neurological
  • Immunological Disorders

By Country:

  • The United States
  • Canada
  • Rest of North America

Geographically, North America had the biggest share in the global biomarkers market in 2020. The increasing use of biomarkers in personalized medicine, diverse growth methods used by important players with established pharmaceutical corporations in this region, and a higher biomarker acceptance rate for disease diagnosis, can all be attributed to this region’s large share.

Biomarkers are becoming more widely utilized to diagnose diseases like cancer, infectious diseases, cardiovascular disorders, and neurological disorders. The increasing use of biomarkers is one of the primary factors driving the diagnostics segment of the biomarkers market forward.

The U.S. biomarkers market accounted for the most significant share in the North American market in 2020. According to the US National Library of Medicine, there are roughly 1,515 cancer biomarkers in clinical studies. In the forecast period, the release of new cancer biomarkers will raise the market size of biomarkers. The cancer biomarker market is dominated by breast and lung cancer, and these instances are expected to rise in the coming years. As a result, the biomarker revenue will increase during the projection period.

In North America, the Canadian biomarkers market is second only to the United States. The elderly population of Canada is looking forward to the Canadian Market. Every year, a considerable number of people are diagnosed with cancer. Lung cancer and prostate cancer are more common in this region, so the government is investing more in healthcare.


A few of the noteworthy companies operating in the North American biomarkers market profiled in this report are Bio-Rad Laboratories (U.S.), Qiagen N.V. (Netherlands), Enzo Biochem (U.S.), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), EKF Diagnostics Holdings plc. (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France), and Signosis, Inc. (U.S.).

  1. Introduction

                1.1 Market Definition                                                                    

                1.2 Study Deliverables                                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                                          

                1.4 General Study Assumptions                                                                

  1. Research Methodology

                2.1 Introduction                                                                               

                2.2 Research Phases                                                                      

                                2.2.1 Secondary Research                                                           

                                2.2.2 Primary Research                                                 

                                2.2.3 Econometric Modelling                                                      

                                2.2.4 Expert Validation                                                  

                2.3 Analysis Design                                                                         

                2.4 Study Timeline                                                                          

  1. Overview

                3.1 Executive Summary                                                                

                3.2 Key Inferences                                                                         

                3.3 New Developments                                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                                          

                4.2 Market Restraints                                                                    

                4.3 Key Challenges                                                                         

                4.4 Current Opportunities in the Market                                                                              

  1. Market Segmentation

                5.1          Product                                                               

                                5.1.1 Introduction                                                           

                                5.1.2 Consumables                                                         

                                5.1.3 Software                                                  

                                5.1.4 Services     Growth Hormone Therapy                                         

                5.2          Type                                                     

                                5.2.1 Introduction                                                           

                                5.2.2 Safety Biomarkers                                                               

                                5.2.3 Efficacy Biomarkers                                                             

                                5.2.4 Validation Biomarkers                                                        

                5.3          Application                                                        

                                5.3.1 Introduction                                                           

                                5.3.2 Diagnostics Development                                                 

                                5.3.3 Drug Discovery and Development                                                

                                5.3.4 Personalised Medicine                                                      

                                5.3.5 Disease Risk Assessment                                                  

                                5.3.6 Other Applications                                                               

                5.4          Disease Indications                                                        

                                5.4.1 Introduction                                                           

                                5.4.2 Cancer                                                      

                                5.4.3 CardiovascularDisorders                                                    

                                5.4.4 Neurological Disorders                                                       

                                5.4.5 Immunological Disorders                                                  

                                5.4.6 Other Diseases                                                      

  1. Geographical Analysis

                                6.1 Introduction                                                               

                                6.2 United States                                                            

                                6.3 Canada                                                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                                                         

                                7.1.1 Political                                                     

                                7.1.2 Economic                                                 

                                7.1.3 Social                                                         

                                7.1.4 Technological                                                         

                                7.1.5 Legal                                                          

                                7.1.6 Environmental                                                       

                7.2 Porter’s Five analysis                                                                              

                                7.2.1 Bargaining Power of Suppliers                                                        

                                7.2.2 Bargaining Power of Consumers                                                    

                                7.2.3 Threat of New Entrants                                                     

                                7.2.4 Threat of Substitute Products and Services                                                              

                                7.2.5 Competitive Rivalry within the Industry                                                     

  1. Market Leaders' Analysis

                8.1 Bio-Rad Laboratories (U.S.)                                                 

                                8.1.1 Overview                                                 

                                8.1.2 Product Analysis                                                   

                                8.1.3 Strategic Evaluation and Operations                                                            

                                8.1.4 Financial analysis                                                  

                                8.1.5 Legal issues                                                             

                                8.1.6 Recent Developments                                                       

                                8.1.7 SWOT analysis                                                       

                                8.1.8 Analyst View                                                          

                8.2 Qiagen N.V. (Netherlands)                                                  

                8.3 Enzo Biochem (U.S.)                                                               

                8.4 PerkinElmer, Inc. (U.S.)                                                         

                8.5 Merck & Co, Inc. (U.S.)                                                          

                8.6 EKF Diagnostics Holdings plc. (U.S.)                                                  

                8.7 Meso Scale Diagnostics, LLC (U.S.)                                                    

                8.8 Singulex, Inc. (U.S.)                                                 

                8.9 BioSims Technologies (France)                                                           

                8.10 Cisbio Bioassays (France)                                                   

                8.11 Signosis, Inc. (U.S.)                                                               

  1. Competitive Landscape

                9.1 Market share analysis                                                                            

                9.2 Merger and Acquisition Analysis                                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                                         

                9.4 New Product Launches                                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                                     

                10.2 Investment Opportunities                                                                 


  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Biomarkers Market By Region, From 2021 to 2026 (USD Million)
  2. North America Biomarkers Market By Product, From 2021 to 2026 (USD Million)
  3. North America Consumables Market By Region, From 2021 to 2026 (USD Million)
  4. North America Software Market By Region, From 2021 to 2026 (USD Million)
  5. North America Services Market By Region, From 2021 to 2026 (USD Million)
  6. North America Biomarkers Market By Type, From 2021 to 2026 (USD Million)
  7. North America Safety Biomarkers Market By Region, From 2021 to 2026 (USD Million)
  8. North America Efficacy Biomarkers Market By Region, From 2021 to 2026 (USD Million)
  9. North America Validation Biomarkers Market By Region, From 2021 to 2026 (USD Million)
  10. North America Biomarkers Market By Application, From 2021 to 2026 (USD Million)
  11. North America Diagnostics Development Market By Region, From 2021 to 2026 (USD Million)
  12. North America Drug Discovery and Development Market By Region, From 2021 to 2026 (USD Million)
  13. North America Personalised Medicine Market By Region, From 2021 to 2026 (USD Million)
  14. North America Disease Risk Assessment Market By Region, From 2021 to 2026 (USD Million)
  15. North America Other Applications Market By Region, From 2021 to 2026 (USD Million)
  16. North America Biomarkers Market By Disease Indications, From 2021 to 2026 (USD Million)
  17. North America Cancer Market By Region, From 2021 to 2026 (USD Million)
  18. North America Cardiovascular Disorders Market By Region, From 2021 to 2026 (USD Million)
  19. North America Neurological Disorders Market By Region, From 2021 to 2026 (USD Million)
  20. North America Immunological Disorders Market By Region, From 2021 to 2026 (USD Million)
  21. North America Other Diseases Market By Region, From 2021 to 2026 (USD Million)
  22. United States Biomarkers Market By Product, From 2021 to 2026 (USD Million)
  23. United States Biomarkers Market By Type, From 2021 to 2026 (USD Million)
  24. United States Biomarkers Market By Application, From 2021 to 2026 (USD Million)
  25. United States Biomarkers Market By Disease Indications, From 2021 to 2026 (USD Million)
  26. Canada Biomarkers Market By Product, From 2021 to 2026 (USD Million)
  27. Canada Biomarkers Market By Type, From 2021 to 2026 (USD Million)
  28. Canada Biomarkers Market By Application, From 2021 to 2026 (USD Million)
    1. Canada Biomarkers Market By Disease Indications, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports


$ 1234 3335

Click for Request Sample